Filing Analysis
FibroBiologics, Inc. has increased the maximum aggregate offering price of its At The Market (ATM) offering to $7.5 million. The company is selling shares through H.C. Wainwright & Co., LLC and reported that 71,830 shares have already been sold under the agreement.
Red Flags
- Potential for ongoing shareholder dilution as the company sells shares 'at the market'.
- Reliance on ATM offerings for capital can indicate a lack of traditional institutional financing options for a micro-cap company.
Key Facts
- The company filed an Updated ATM Prospectus Supplement on May 5, 2026, to increase the offering capacity to $7,500,000.
- The Sales Agent for the ATM offering is H.C. Wainwright & Co., LLC.
- As of the filing date, 71,830 shares of common stock have already been sold under the Sales Agreement.
- The offering utilizes the company's shelf registration statement on Form S-3 (No. 333-284663) which became effective on February 10, 2025.
FibroBiologics, Inc. granted stock options to its core executive team, including the CEO, CFO, CSO, and General Counsel, under the company's 2022 Stock Plan.
Key Facts
- Grant date: May 4, 2026
- CEO Pete O'Heeron received options for 92,410 shares
- CFO Jason D. Davis, CSO Hamid Khoja, and GC Ruben A. Garcia each received options for 61,607 shares
- Exercise price for all options is $1.38 per share
- Vesting schedule: 25% after one year, followed by 36 equal monthly installments (4-year total vesting)
FibroBiologics, Inc. has entered into an At The Market (ATM) Offering Agreement with H.C. Wainwright & Co., LLC to sell up to $6.15 million of its common stock. The company intends to use the proceeds for working capital and general corporate purposes.
Red Flags
- Potential dilution of existing shareholders through the issuance of up to $6.15 million in new equity.
Key Facts
- Entered into an ATM agreement on May 1, 2026, with H.C. Wainwright & Co., LLC.
- Maximum aggregate offering price of $6,150,000.
- Sales agent receives a 3.0% commission on gross proceeds.
- Company to reimburse agent for $100,000 in legal fees and ongoing due diligence costs ranging from $3,500 to $5,000 per update.
- Shares will be issued under an existing S-3 shelf registration statement (No. 333-284663) effective since February 10, 2025.
FibroBiologics has regained compliance with Nasdaq's minimum bid price and stockholders' equity requirements, closing previously disclosed listing matters. However, the company is now subject to a Mandatory Panel Monitor for one year, which eliminates standard cure periods for future non-compliance.
Red Flags
- Mandatory Panel Monitor status indicates a history of significant listing non-compliance.
- Loss of standard cure periods for the next 12 months increases the risk of sudden delisting.
- The company previously struggled with both minimum bid price and stockholders' equity simultaneously.
Key Facts
- Confirmed compliance with Nasdaq Bid Price Rule 5550(a)(2) on April 17, 2026.
- Confirmed compliance with Nasdaq Stockholders' Equity Rule 5550(b)(1) on March 9, 2026.
- Placed under a Mandatory Panel Monitor for one year for both bid price and equity requirements.
- Any failure to maintain compliance during the monitor period will result in an immediate delist determination without a cure period.
FibroBiologics, Inc. amended its bylaws to significantly reduce the quorum requirement for stockholder meetings from a majority of voting power to just one-third.
Red Flags
- Lowering quorum requirements to one-third allows corporate actions to be approved by a smaller minority of shareholders, potentially reducing oversight.
- Such changes often indicate the company has had difficulty achieving a majority quorum in the past or anticipates difficulty passing upcoming proposals.
Key Facts
- On April 16, 2026, the Board of Directors approved an amendment to Section 2.07 of the Company’s Amended and Restated Bylaws.
- The quorum requirement for stockholder meetings was lowered from a majority (over 50%) to one-third (33.3%) of the voting power.
- The amendment was effective immediately as of the Board's approval date.
FibroBiologics, Inc. entered into a Sublease Buyout Agreement to terminate its office lease in Webster, Texas, effective April 2, 2026, approximately 18 months ahead of schedule. The company paid $45,108.25 to exit the lease and expects to save approximately $0.8 million in future rent payments by consolidating operations into its new Houston facility.
Key Facts
- Terminated sublease with United Fire & Casualty Co. effective April 2, 2026.
- The original sublease expiration date was November 30, 2027.
- A one-time buyout payment of $45,108.25 was made to resolve remaining rent obligations.
- The company expects to save approximately $0.8 million in future rent payments.
- Operations are being consolidated into a 10,000 square foot laboratory facility opened in 2025.
- The principal executive office address changed to 9350 Kirby Drive, Suite 300, Houston, Texas 77054.
FibroBiologics, Inc. implemented a 1-for-20 reverse stock split effective March 30, 2026. The split consolidated every twenty shares of common stock into one share, resulting in a change to the CUSIP number but maintaining the same trading symbol.
Red Flags
- Significant 1-for-20 reverse split ratio often indicates a struggle to maintain minimum bid price requirements for Nasdaq listing.
- Authorized shares were not reduced in proportion to the split, which significantly increases the potential for future equity dilution.
Key Facts
- Reverse stock split ratio of 1-for-20 effective March 30, 2026.
- Fractional shares are rounded up to the nearest whole share.
- The CUSIP number for the Common Stock changed to 31573L204.
- The authorized number of shares of Common Stock remained unchanged despite the split.
- The par value of the Common Stock remains $0.00001 per share.
FibroBiologics, Inc. closed a best-efforts public offering on April 2, 2026, generating approximately $2.5 million in net proceeds. The offering involved the sale of common stock and pre-funded warrants, each bundled with a common warrant, with the exercisability of the common warrants contingent upon future stockholder approval.
Red Flags
- The 'best-efforts' nature of the offering suggests a lack of firm commitment from underwriters.
- Highly dilutive structure with 100% warrant coverage (one warrant for every share/pre-funded warrant sold).
- Exercisability of warrants is contingent on stockholder approval, indicating potential regulatory or authorized share hurdles.
- Small net raise of $2.5 million for a public company suggests a high burn rate or urgent liquidity needs.
- Restriction on 'Variable Rate Transactions' for one year suggests a history of or attempt to avoid 'death spiral' financing.
Key Facts
- The offering consisted of 1,028,788 shares of common stock and 1,243,940 pre-funded warrants.
- The combined offering price was $1.32 per share and accompanying warrant.
- Net proceeds were approximately $2.5 million after fees and expenses.
- Common warrants have an exercise price of $1.32 but cannot be exercised until stockholder approval is obtained.
- H.C. Wainwright & Co., LLC served as the placement agent, receiving an 8% total fee and placement agent warrants for 159,091 shares.
- Executive officers and directors are subject to a 30-day lock-up period following the closing.
FibroBiologics, Inc. announced a base salary increase for its Chief Financial Officer, Jason D. Davis, to $400,000 effective January 1, 2026. The executive's target bonus remains at 40% of his base salary.
Key Facts
- CFO Jason D. Davis's annual base salary increased to $400,000.
- The salary adjustment is retroactive to an effective date of January 1, 2026.
- Target non-equity incentive compensation remains unchanged at 40% of base salary.
- The change was approved by the Compensation Committee on March 4, 2026.
FibroBiologics, Inc. (FBLG) held a Special Meeting of Stockholders on February 20, 2026, at which shareholders approved five proposals including a reverse stock split at a ratio of 1-for-5 to 1-for-30 (exact ratio at Board's discretion), as well as Nasdaq Rule 5635(d) approvals for the issuance of shares underlying warrants from three separate Securities Purchase Agreements executed in November and December 2025. The combination of a pending reverse split and multiple rounds of warrant-based dilutive financing signals significant financial stress for this clinical-stage biologic company. All five proposals passed with strong majorities (~97% of votes cast in favor).
Red Flags
- Reverse stock split authorized at an aggressive range of up to 1-for-30, strongly suggesting the stock price has fallen or is at risk of falling below Nasdaq's $1.00 minimum bid price requirement
- Three separate Securities Purchase Agreements executed in rapid succession (Nov 18, Nov 24, and Dec 14, 2025) indicates urgent, repeated capital raises over a compressed ~4-week period
- Aggregate potential dilution of ~22.5 million new shares from warrant exercises against a current share base of ~99 million shares (~22.7% dilution)
- Nasdaq Rule 5635(d) shareholder approval required for all three financing tranches, confirming each was a below-market or discounted private placement
- H.C. Wainwright & Co. LLC received warrants as placement agent compensation across multiple deals, adding additional dilution on top of investor warrants
- Board granted unilateral discretion to set split ratio and timing without further stockholder input, concentrating significant decision-making power
Key Facts
- Special Meeting held February 20, 2026; 54,974,113 of 99,019,722 eligible votes represented (~55.5% quorum)
- Proposal 1 APPROVED: Reverse stock split authorized at ratio of 1-for-5 to 1-for-30, exact ratio set at Board's discretion, effective within one year of stockholder approval (by ~Feb 20, 2027)
- Proposal 2 APPROVED: Issuance of up to 12,110,203 shares upon exercise of warrants from Securities Purchase Agreement dated November 18, 2025
- Proposal 3 APPROVED: Issuance of up to 4,477,614 shares from warrants per Securities Purchase Agreements dated November 24, 2025, plus 313,433 shares for H.C. Wainwright & Co. LLC engagement letter warrants
- Proposal 4 APPROVED: Issuance of up to 5,227,275 shares from warrants per Securities Purchase Agreements dated December 14, 2025, plus 365,909 shares for H.C. Wainwright & Co. LLC engagement letter warrants
- Proposal 5 APPROVED: Adjournment authority granted to Board if needed
- Total potential dilutive shares from warrant issuances: approximately 22,494,434 shares
- Record date for Special Meeting: December 26, 2025
- Filing signed by CEO Pete O'Heeron on February 23, 2026
- FBLG is an emerging growth company listed on Nasdaq; common stock par value $0.00001